文献

J-GLOBAL ID：201702232611112590   整理番号：17A0081168

日本人患者でのスタチン関連ミオパシーにおけるHLA-DRB1^*04:06についての可能性としての役割

A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients

著者 (29件)： Sai Kimie (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan) ,  Kajinami Kouji (Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Akao Hironobu (Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Iwadare Mizuho (Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Sato-Ishida Ryoko (Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Kawai Yasuyuki (Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Takeda Kenji (Department of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Tanimoto Takashi (Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan) ,  Yamano Takashi (Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan) ,  Akasaka Takashi (Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan) ,  Ishida Tatsuro (Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan) ,  Hirata Ken-ichi (Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan) ,  Saku Keijiro (Department of Cardiology, Fukuoka University School of Medicine, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan) ,  Yagi Shusuke (Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, 2-24, Shinkura-cho, Tokushima 770-8501, Japan) ,  Soeki Takeshi (Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, 2-24, Shinkura-cho, Tokushima 770-8501, Japan) ,  Sata Masataka (Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, 2-24, Shinkura-cho, Tokushima 770-8501, Japan) ,  Ueno Masafumi (Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, 377-2, Ono-Higashi, Osaka-Sayama, Osaka 589-8511, Japan) ,  Miyazaki Shunichi (Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, 377-2, Ono-Higashi, Osaka-Sayama, Osaka 589-8511, Japan) ,  Shiraki Aya (Department of Cardiovascular Medicine, Saga University, 1 Honjo-machi, Saga 840-8502, Japan) ,  Oyama Jun-ichi (Department of Cardiovascular Medicine, Saga University, 1 Honjo-machi, Saga 840-8502, Japan) ,  Node Koichi (Department of Cardiovascular Medicine, Saga University, 1 Honjo-machi, Saga 840-8502, Japan) ,  Sugamura Koichi (Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan) ,  Ogawa Hisao (Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan) ,  Kurose Kouichi (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan) ,  Maekawa Keiko (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan) ,  Matsuzawa Yumiko (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan) ,  Imatoh Takuya (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan) ,  Hasegawa Ryuichi (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan) ,  Saito Yoshiro (Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan)
資料名： Drug Metabolism and Pharmacokinetics (Web)  (Drug Metabolism and Pharmacokinetics (Web))
巻： 31  号： 6  ページ： 467-470  発行年： 2016年12月 
JST資料番号： U0705A  ISSN： 1347-4367  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： スタチン関連ミオパシー(SRM)は臨床的に重要な有害反応であ...

シソーラス用語： *HMG-CoAレダクターゼ阻害剤 ,...
準シソーラス用語： *HLA-DRB1 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0081168&from=J-GLOBAL&jstjournalNo=U0705A") }}

著者キーワード (5件)： Statin ,  Myopathy ,  Rhabdomyolysis ,  Genetic polymorphism ,  HLA

分類 (2件)： 中毒一般  (GD06010Q) ,  脂質代謝作用薬の臨床への応用  (GW13050X)

引用文献 (18件)：

• Tompkins R, Schwartzbard A, Gianos E, Fisher E, Weintraub H. A current approach to statin intolerance. Clin Pharmacol Ther 2014;96:74-80.
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. J Am Med Assoc 2003;289:1681-90.
• Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40.
• Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004;49:582-5.
• FerrariM,Guasti L,Maresca A, Mirabile M, Contini S, Grandi AM, et al. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol 2014;70:539-47.

タイトルに関連する用語 (6件)： 日本人 ,  患者 ,  スタチン ,  ミオパシー ,  可能性 ,  役割